congenital heart disease
Conditions
Interventions
biomarker
congenital heart diseases
pulmonary arterial hypertension
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: In this study we will include patients aged 0-18 years with a (history of) pressure- and/or volume-loaded right ventricle due to congenital heart disease and/or pulmonary arterial hypertension, seen in the University Medical Centre Groningen-Centre for Congenital Heart Diseases (UMCG-CCH) between 01-09-2017 and 01-09-2021.
Exclusion criteria
Exclusion criteria: - > 18 years of age - no echocardiography within three months before or after blood collection - pregnant - concomitant musculoskeletal disease - being under examination for non-diagnosed disease at time of investigation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Our primary objective is to investigate cross-sectionally the association between various emerging blood-derived biomarkers and right ventricular (RV) function:defined as tricuspid annular plane systolic excursion (TAPSE) measured with echocardiography, in children with (a history of ) an abnormally loaded, volume and/or pressure loaded, right ventricle associated with CHD and/or PAH. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary (exploratory) Objective(s): Furthermore, we aim to explore: - The stability, dynamic (treatment-induced) longitudinal changes of these biomarkers and their association with RV function (defined as TAPSE). - The predictive value of these biomarkers measured at baseline with regard to various clinically relevant impaired RV functioning parameters (TAPSE, RV- Fractional area change , RV-Fractional shortening and RV function assessed with eyeballing) at long term follow-up. - The predictive value of these biomarkers with regard to clinical outcome defined as the composite of mortality, hospitalization, and or heart/lung transplantation. | — |
Countries
The Netherlands
Outcome results
None listed